Abstract
This is a retrospective analysis of Fabry Outcome Survey data from children/adults (n=677) receiving agalsidase alfa enzyme replacement therapy for a median of 3years, examining cerebrovascular, cardiac, and renal morbidity endpoints separately. Cardiac events occurred at younger ages than cerebrovascular or renal events, cerebrovascular events were more frequent in females than males, and males were more likely to experience cardiac and renal events at a younger age than females.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have